← Back to Search

Topical Agent

VTAMA (tapinarof) cream, 1% for Psoriasis

Phase 4
Waitlist Available
Research Sponsored by Dermavant Sciences, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to week 12
Awards & highlights
No Placebo-Only Group
Pivotal Trial
Drug Has Already Been Approved

Summary

This trial is testing a cream called VTAMA that contains 1% tapinarof. It is aimed at adults who have plaque psoriasis on their head and neck. The cream works by calming the skin and reducing the overproduction of skin cells, which helps with the red and scaly patches.

Eligible Conditions
  • Psoriasis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to week 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to week 12 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Percentage of Participants Who Achieve a Target Lesion Physician Global Assessment (PGA) Score in the Head and Neck Region of Clear (0) or Almost Clear (1) With a ≥ 2-grade Improvement
Secondary study objectives
Time to Achieve a Target Lesion PGA Score of Clear (0) or Almost Clear (1) With a ≥ 2-grade Improvement

Side effects data

From 2023 Phase 4 trial • 31 Patients • NCT05789576
23%
Dermatitis contact
19%
Folliculitis
16%
Headache
6%
Sinusitis
6%
Seborrheic keratosis
3%
Rectal haemorrhage
3%
Anaemia
100%
80%
60%
40%
20%
0%
Study treatment Arm
VTAMA (Tapinarof) Cream, 1%

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.

Trial Design

1Treatment groups
Experimental Treatment
Group I: VTAMA (tapinarof) cream, 1%Experimental Treatment1 Intervention
VTAMA (tapinarof) cream, 1% applied topically once daily
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
VTAMA (tapinarof) cream, 1%
2023
Completed Phase 4
~40

Find a Location

Who is running the clinical trial?

Dermavant Sciences, Inc.Lead Sponsor
8 Previous Clinical Trials
1,990 Total Patients Enrolled
3 Trials studying Psoriasis
174 Patients Enrolled for Psoriasis
Philip Brown, MD, JDStudy DirectorChief Medical Officer, Dermavant Sciences, Inc.

Media Library

VTAMA (tapinarof) cream, 1% (Topical Agent) Clinical Trial Eligibility Overview. Trial Name: NCT05789576 — Phase 4
Psoriasis Research Study Groups: VTAMA (tapinarof) cream, 1%
Psoriasis Clinical Trial 2023: VTAMA (tapinarof) cream, 1% Highlights & Side Effects. Trial Name: NCT05789576 — Phase 4
VTAMA (tapinarof) cream, 1% (Topical Agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05789576 — Phase 4
~12 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top